Description


There is on-going development of  generic EU CTD Dossier of  Esomeprazole, enteric coated tablets, 20/40 mg.





Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.



Esomeprazole is a proton pump inhibitor (brand names Sompraz, Zoleri, Nexium, Lucen, Esopral; Axagon in Italy, Nexiam in Belgium) developed and marketed by AstraZeneca which is used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome. Esomeprazole is the S-enantiomer of omeprazole (marketed as Losec/Prilosec), and AstraZeneca claims improved efficacy of this single enantiomer product over the racemic mixture of omeprazole. However, this greater efficacy has been disputed, with some[who?] claiming it offers no benefit from its older form.



More details at: http://www.rxlist.com/nexium-drug.htm.


More details

Name Description
Pharma licensing Out-licensing (offer)

Ad details

Ad ID : 32
Contact Advertiser

Add comment

 
Related adverts
 

Phone number

Sorry, you need to register or login first.

Email

Sorry, you need to register or login first.

Contact form

Sorry, you need to register or login first.

What's wrong with this ad?

Sorry, you need to register or login first.

Add to favorites

Sorry, you need to register or login first.